StageUnattributed | Alive
Last Raised$2.06M | 2 yrs ago
Missing: Neuropharma's Product Demo & Case Studies
Promote your product offering to tech buyers.
Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.
Missing: Neuropharma's Product & Differentiators
Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).
Latest Neuropharma News
Mar 24, 2023
Impel NeuroPharma press release (NASDAQ: IMPL ): Q4 Non-GAAP EPS of -$0.97 beats by $0.06. Revenue of $5.01M (+735.0% Y/Y) misses by $0.24M. As of December 31, 2022, Impel had approximately $60.7 million in cash and cash equivalents. The Company believes, based on its current operating plan, that it has sufficient capital to fund operations into the third quarter of 2023. To-date, Trudhesa continues a strong trajectory with more than 58,400 prescriptions generated in 2022. Based on third-party data, it is estimated that at the end of December Trudhesa accounted for 4.3 percent of branded acute migraine prescriptions (nTRx) among prescribers. Shares +3.82% PM The Company projects Trudhesa will deliver prescriptions within the range of 80,000 – 110,000 TRx for full year 2023. Recommended For You
Neuropharma Frequently Asked Questions (FAQ)
Where is Neuropharma's headquarters?
Neuropharma's headquarters is located at 52 White Pine Canyon Road, Park City.
What is Neuropharma's latest funding round?
Neuropharma's latest funding round is Unattributed.
How much did Neuropharma raise?
Neuropharma raised a total of $2.06M.
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.